User Profile
Corporate
Careers
FAQ
Blog
Pricing
Social
General Modals
Advanced Modals
Search
Wizards
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
The purpose of this notice of funding opportunity (NOFO) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD. The primary objective of this NOFO is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.
The UG3/UH3 Cooperative Agreement involves two phases. The UG3 phase, for up to two years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to three additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by the National Institute on Drug Abuse (NIDA) and prioritized for transition to the UH3 phase. Investigators submitting to this NOFO must address both UG3 and UH3 phases.
Deadlines:
- Letter of Intent Due Date(s):30 days prior to the application due date
- Applications: March 26, 2024; July 17, 2024; Nov 19, 2024; March 26, 2025; July 17, 2025; Nov 19, 2025; March 26, 2026; July 17, 2026; Nov 19, 2026
PAR-24-064 Expiration Date November 20, 2026
Specialties
Eligibility Requirements
Sponsor Details
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Grant
Final Deadline:
Nov 19, 2024
Funding Amount:
Varies
Host Details
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.
Invite Gmail Contacts